Mineralys Therapeutics, Inc.
lorundrostat
hypertension
Countdown
168days
FDA decision · Dec 22, 2026
What's at stake
The FDA's approval decision on lorundrostat for hypertension is due Dec 22, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 14h ago
“The FDA also assigned a Prescription Drug User Fee Act target action date of December 22, 2026.”